Business Context and Reporting Period
Company: Kestra Medical Technologies, Ltd. (KMTS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended January 31, 2026
Business Overview: Kestra is a commercial-stage medical device company focused on the Cardiac Recovery System platform, anchored by the ASSURE Wearable Cardioverter Defibrillator (WCD). The company generates revenue primarily through leasing the ASSURE WCD to patients, billing third-party payors (Medicare, Medicaid, private insurers) and patients for co-payments. The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Jan 31, 2026 | Nine Months Ended Jan 31, 2026 | Balance Sheet (Jan 31, 2026) |
|---|---|---|---|
| Revenue | $24,552 | $66,488 | - |
| Gross Profit | $12,906 | $33,181 | - |
| Gross Margin | 52.6% | 49.9% | - |
| Net Loss | $(34,166) | $(92,777) | - |
| Operating Cash Flow | - | $(62,983) | - |
| Cash and Equivalents | - | - | $291,321 |
| Long-Term Debt (Net) | - | - | $42,261 |
| Accumulated Deficit | - | - | $(613,026) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 63% year-over-year (YoY) for the quarter and 56% for the nine-month period, driven by a 58% and 55% increase in the number of patients, respectively.
- Expense Expansion: Selling, General, and Administrative (SG&A) expenses surged 79% for the quarter and 78% for the nine-month period. This was primarily due to increased personnel costs (salaries, benefits, share-based compensation) to support commercial growth and higher costs associated with being a public company.
- Profitability: While gross profit increased 97% (quarter) and 100% (nine months) due to revenue growth and improved equipment utilization, the company reported a net loss of $34.2 million for the quarter and $92.8 million for the nine months, compared to $21.8 million and $62.7 million in the prior year periods.
- Accounting Change: The company prospectively changed the estimated useful life of medical rental equipment from 2-8 years to 2-15 years, reducing depreciation expense by $0.7 million in the quarter.
- Capital Raise: In December 2025, the company completed a secondary offering of 6.9 million shares, raising net proceeds of approximately $149.3 million.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash ($291.3 million) and revenue will fund operations for at least the next 12 months. However, the company expects to continue incurring net losses as it scales its commercial organization.
- Debt Covenants: The company has a $60 million Term Loan facility with $45 million currently drawn. An additional $15 million tranche is available through July 31, 2026, contingent on achieving a trailing twelve-month revenue run rate of $60 million. The company was in compliance with all covenants as of January 31, 2026.
- Strategic Collaboration: Entered a collaboration with Biobeat Technologies in December 2025 to integrate cuffless blood pressure monitoring, with potential R&D funding up to $2 million and a $5 million equity investment.
- Material Weaknesses: The company disclosed that its disclosure controls and procedures were not effective as of January 31, 2026, due to material weaknesses in internal controls over financial reporting. These include insufficient resources in accounting/IT, lack of controls for complex transactions, and deficiencies in IT general controls (segregation of duties, change management).
- Risk Factors: Key risks include the ability to maintain regulatory approvals, reimbursement availability, scaling manufacturing, and the potential need for additional financing if growth plans require more capital than currently available.
Investor Verification Checklist
- Internal Controls: Verify the progress of remediation plans for the disclosed material weaknesses in internal controls over financial reporting and IT general controls.
- Debt Milestones: Monitor the company's ability to achieve the $60 million trailing twelve-month revenue run rate required to access the remaining $15 million tranche of its term loan.
- Burn Rate vs. Revenue: Assess the trajectory of SG&A expenses relative to revenue growth to determine the path to operating breakeven.
- Reimbursement Rates: Confirm stability in reimbursement rates from Medicare and private payors, as revenue is heavily dependent on third-party billing.
- Equipment Utilization: Review the impact of the accounting change regarding the useful life of medical rental equipment on future depreciation and cost of revenue.